Two former high-ranking pharmaceutical executives are leading a new Cambridge, Mass., biotech that has received $58 million in venture capital to develop treatments for disorders related to the immune system.
Anthony J. Coyle, a former senior vice president at Pfizer (PFE), has been named chief executive, and Jo Viney, a former senior vice president at Biogen (BIIB), will become chief scientific officer of the newly founded Pandion Therapeutics, the company said Thursday.
